Filtered By:
Vaccination: Malaria Vaccine
This page shows you your search results in order of date. This is page number 15.
Order by Relevance | Date
Total 1513 results found since Jan 2013.
Licensed liposomal vaccines and adjuvants in the antigen delivery system
BioTechnologia (Pozn). 2022 Dec 24;103(4):409-423. doi: 10.5114/bta.2022.120709. eCollection 2022.ABSTRACTLiposomes (LSs) are promising nanoparticles with unique properties such as controlled nanosize, large surface area, increased reactivity, and ability to undergo modification. Worldwide, licensed liposomal forms of antibiotics, hormones, antioxidants, cytostatics, ophthalmic drugs, etc., are available on the pharmaceutical market. This review focuses on the adjuvant properties of LSs in the production of vaccines (VACs). LS-VACs have the following advantages: antigens with low immunogenicity can become highly immunogeni...
Source: Herpes - January 23, 2023 Category: Infectious Diseases Authors: Yuriy Krasnopolsky Daria Pylypenko Source Type: research
Plasmodium DDI1 is a potential therapeutic target and important chromatin-associated protein
Int J Parasitol. 2023 Jan 16:S0020-7519(23)00013-9. doi: 10.1016/j.ijpara.2022.11.007. Online ahead of print.ABSTRACTDNA damage inducible 1 protein (DDI1) is involved in a variety of cellular processes including proteasomal degradation of specific proteins. All DDI1 proteins contain a ubiquitin-like (UBL) domain and a retroviral protease (RVP) domain. Some DDI1 proteins also contain a ubiquitin-associated (UBA) domain. The three domains confer distinct activities to DDI1 proteins. The presence of a RVP domain makes DDI1 a potential target of HIV protease inhibitors, which also block the development of malaria parasites. He...
Source: International Journal for Parasitology - January 19, 2023 Category: Parasitology Authors: Nandita Tanneru M Angel Nivya Navin Adhikari Kanika Saxena Zeba Rizvi Renu Sudhakar Amit Kumar Nagwani None Atul Faisal Mohammed Abdul Al-Nihmi Kota Arun Kumar Puran Singh Sijwali Source Type: research
Immunomodulation through vaccination as a promising therapeutic strategy to mitigate malaria-related neurocognitive sequelae
Brain Behav Immun. 2023 Jan 16:S0889-1591(23)00007-7. doi: 10.1016/j.bbi.2023.01.007. Online ahead of print.ABSTRACTMalaria, an ancient infectious parasitic disease, is caused by protozoa of the genus Plasmodium, whose erythrocytic cycle is accompanied by fever, headache, sweating and chills and a systemic inflammation that can progress to severe forms of disease, including cerebral malaria. Approximately 25% of survivors of this syndrome develop sequelae that may include neurological, neurocognitive, behavioral alterations and poor school performance. Furthermore, some outcomes have also been recorded following episodes o...
Source: Brain, Behavior, and Immunity - January 19, 2023 Category: Neurology Authors: Pamela Rosa-Gon çalves Luciana Pereira de Sousa Fl ávia Lima Ribeiro-Gomes Leonardo Jos é de Moura Carvalho Cl áudio Tadeu Daniel-Ribeiro Source Type: research
Plasmodium DDI1 is a potential therapeutic target and important chromatin-associated protein
Int J Parasitol. 2023 Jan 16:S0020-7519(23)00013-9. doi: 10.1016/j.ijpara.2022.11.007. Online ahead of print.ABSTRACTDNA damage inducible 1 protein (DDI1) is involved in a variety of cellular processes including proteasomal degradation of specific proteins. All DDI1 proteins contain a ubiquitin-like (UBL) domain and a retroviral protease (RVP) domain. Some DDI1 proteins also contain a ubiquitin-associated (UBA) domain. The three domains confer distinct activities to DDI1 proteins. The presence of a RVP domain makes DDI1 a potential target of HIV protease inhibitors, which also block the development of malaria parasites. He...
Source: International Journal for Parasitology - January 19, 2023 Category: Parasitology Authors: Nandita Tanneru M Angel Nivya Navin Adhikari Kanika Saxena Zeba Rizvi Renu Sudhakar Amit Kumar Nagwani None Atul Faisal Mohammed Abdul Al-Nihmi Kota Arun Kumar Puran Singh Sijwali Source Type: research
Immunomodulation through vaccination as a promising therapeutic strategy to mitigate malaria-related neurocognitive sequelae
Brain Behav Immun. 2023 Jan 16;109:102-104. doi: 10.1016/j.bbi.2023.01.007. Online ahead of print.ABSTRACTMalaria, an ancient infectious parasitic disease, is caused by protozoa of the genus Plasmodium, whose erythrocytic cycle is accompanied by fever, headache, sweating and chills and a systemic inflammation that can progress to severe forms of disease, including cerebral malaria. Approximately 25% of survivors of this syndrome develop sequelae that may include neurological, neurocognitive, behavioral alterations and poor school performance. Furthermore, some outcomes have also been recorded following episodes of non-seve...
Source: Brain, Behavior, and Immunity - January 19, 2023 Category: Neurology Authors: Pamela Rosa-Gon çalves Luciana Pereira de Sousa Fl ávia Lima Ribeiro-Gomes Leonardo Jos é Moura Carvalho Cl áudio Tadeu Daniel-Ribeiro Source Type: research
A single dose of genetically-attenuated malaria blood-stage parasites protects against two Plasmodium species infections
Vaccine. 2023 Jan 16:S0264-410X(23)00003-8. doi: 10.1016/j.vaccine.2023.01.004. Online ahead of print.ABSTRACTGenetically-growth-attenuated blood-stage parasites were generated inPlasmodium falciparumby targeted deletion of NT1 (Nucleoside Transporter-1) gene, and Pfnt1(-) parasites only grew after providing the culture with supra-physiological concentrations of purines. Genetically-attenuatedP. yoeliint1(-)parasites induced sterile-protection against homologous blood-stage infectious challenge after immunization with single subpatent doses, which remained subpatent even in immune-compromised mice. Here, we showed that imm...
Source: Vaccine - January 18, 2023 Category: Allergy & Immunology Authors: Gozde Deveci Mohd Kamil Ahmed S I Aly Source Type: research
Plasmodium vivax vaccine: What is the best way to go?
Malaria is one of the most devastating human infectious diseases caused by Plasmodium spp. parasites. A search for an effective and safe vaccine is the main challenge for its eradication. Plasmodium vivax is the second most prevalent Plasmodium species and the most geographically distributed parasite and has been neglected for decades. This has a massive gap in knowledge and consequently in the development of vaccines. The most significant difficulties in obtaining a vaccine against P. vivax are the high genetic diversity and the extremely complex life cycle. Due to its complexity, studies have evaluated P. vivax antigens ...
Source: Frontiers in Immunology - January 16, 2023 Category: Allergy & Immunology Source Type: research
Immunodominant T cell peptides from four candidate malarial antigens as biomarkers of protective immunity against malaria
This study extends our previous work which used peripheral blood mononuclear cells (PBMCs) from adults with life-long exposure to malaria parasites to identify immunodominant antigen-specific peptide pools composed of overlapping 15mer sequences spanning full length proteins of four malarial antigens. Our current study aimed to identify CD8 + T cell epitopes within these previously identified positive peptide pools. Cryopreserved PBMCs from 109 HLA-typed subjects were stimulated with predicted 9-11mer CD8 + T cell epitopes from P. falciparum circumsporozoite protein (CSP), apical membrane antigen 1 (AMA1), thrombospondin r...
Source: Vaccine - January 15, 2023 Category: Allergy & Immunology Authors: Maria Belmonte Harini Ganeshan Jun Huang Arnel Belmonte Sandra Inoue Rachel Velasco Neda Acheampong Ebenezer Addo Ofori Kwadwo Akyea-Mensah Augustina Frimpong Nana Aba Ennuson Abena Fremaah Frempong Eric Kyei-Baafour Linda Eva Amoah Kimberly Edgel Bjoern Source Type: research
The mRNA Vaccine Technology Era and the Future Control of Parasitic Infections
This article considers the characteristics that are required to develop a potent antiparasite vaccine and provides a conceptual foundation to promote the development of parasite mRNA-based vaccines. We review the recent advances and challenges encountered in developing antiparasite vaccines and evaluate the potential of developing mRNA vaccines against parasites, including those causing diseases such as malaria and schistosomiasis, against which vaccines are currently suboptimal or not yet available.PMID:36625671 | DOI:10.1128/cmr.00241-21
Source: Clinical Microbiology Reviews - January 10, 2023 Category: Microbiology Authors: Hong You Malcolm K Jones Catherine A Gordon Alexa E Arganda Pengfei Cai Harry Al-Wassiti Colin W Pouton Donald P McManus Source Type: research
